Skip to main content
  • PCSK9 Inhibitor Evolocumab Lowers MACE Risk in Patients with and without Multivessel CAD – FOURIER Long-Term Follow-Up

    Magnitude of benefit greater early in patients with multivessel disease, but it continues to grow over time in all patients taking the drug

    The use of evolocumab reduced the rate of major adverse cardiovascular events (MACE) in patients with known atherosclerotic coronary artery disease (CAD), regardless of whether they had multivessel CAD, but the drug’s benefit was larger and occurred earlier in patients with multivessel disease, a long-term study shows.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details